RU2668794C2 - Композиция, содержащая инкапсулированный антагомир - Google Patents

Композиция, содержащая инкапсулированный антагомир Download PDF

Info

Publication number
RU2668794C2
RU2668794C2 RU2015134770A RU2015134770A RU2668794C2 RU 2668794 C2 RU2668794 C2 RU 2668794C2 RU 2015134770 A RU2015134770 A RU 2015134770A RU 2015134770 A RU2015134770 A RU 2015134770A RU 2668794 C2 RU2668794 C2 RU 2668794C2
Authority
RU
Russia
Prior art keywords
seq
sequence
mir
nucleotide identity
microspheres
Prior art date
Application number
RU2015134770A
Other languages
English (en)
Russian (ru)
Other versions
RU2015134770A (ru
Inventor
Мигель-Анхель АСИН
Эулалия ФЕРРЕТ
Амадэо ПЕРЕЗ
Нёс Белльера ГОТАРДА
СИНОВАС Антонио РОДРИГЕС
Игнаси Барда ВЕРТ
ГАРСИЯ Антонио Давид ГАРСИЯ-ДОРАДО
Original Assignee
Пьер Фабр Медикамент С.А.С.
Фундасио Оспиталь Университари Валь Д'Эброн - Институт Де Ресерка
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пьер Фабр Медикамент С.А.С., Фундасио Оспиталь Университари Валь Д'Эброн - Институт Де Ресерка filed Critical Пьер Фабр Медикамент С.А.С.
Publication of RU2015134770A publication Critical patent/RU2015134770A/ru
Application granted granted Critical
Publication of RU2668794C2 publication Critical patent/RU2668794C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015134770A 2013-01-24 2014-01-23 Композиция, содержащая инкапсулированный антагомир RU2668794C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305082.3A EP2759595B1 (en) 2013-01-24 2013-01-24 Composition comprising an encapsulated antagomir
EP13305082.3 2013-01-24
PCT/IB2014/058500 WO2014115103A1 (en) 2013-01-24 2014-01-23 Composition comprising an encapsulated antagomir

Publications (2)

Publication Number Publication Date
RU2015134770A RU2015134770A (ru) 2017-03-03
RU2668794C2 true RU2668794C2 (ru) 2018-10-02

Family

ID=47683670

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015134770A RU2668794C2 (ru) 2013-01-24 2014-01-23 Композиция, содержащая инкапсулированный антагомир

Country Status (16)

Country Link
US (1) US20150352055A1 (enExample)
EP (2) EP2759595B1 (enExample)
JP (1) JP2016506923A (enExample)
KR (1) KR20160018451A (enExample)
CN (1) CN105229151A (enExample)
AU (1) AU2014208419A1 (enExample)
BR (1) BR112015017650A2 (enExample)
CA (1) CA2898958A1 (enExample)
ES (2) ES2606636T3 (enExample)
HK (1) HK1219753A1 (enExample)
HU (1) HUE032125T2 (enExample)
MX (1) MX2015009323A (enExample)
PL (1) PL2759595T3 (enExample)
RU (1) RU2668794C2 (enExample)
WO (1) WO2014115103A1 (enExample)
ZA (1) ZA201505602B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2864482A4 (en) 2012-06-21 2016-02-10 Miragen Therapeutics Inc OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
HK1249108A1 (zh) * 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
EP3601565A4 (en) * 2017-03-25 2021-01-06 Miragen Therapeutics, Inc. MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE
EP3939575B1 (en) * 2019-03-14 2026-07-01 M. Technique Co., Ltd. PLGA MICROPARTICLES, DELAYED-RELEASE FORMULATION OF THESE AND THEIR MANUFACTURE PROCESS
CN110484537B (zh) * 2019-09-02 2021-07-27 中国水产科学研究院淡水渔业研究中心 一种miR-92促进剂及其注射剂的制备方法和应用
CN110804659B (zh) * 2019-10-23 2023-02-03 华南农业大学 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用
CN110917359A (zh) * 2019-11-21 2020-03-27 武汉理工大学 离子键自组装制备PEG-P（Asp-AP）-ANTAGOMIR-RNA微球
WO2021251526A1 (ko) * 2020-06-11 2021-12-16 주식회사 프로스테믹스 신규한 mirna 유사체 및 이의 용도
CN111729088B (zh) * 2020-08-21 2020-12-15 江苏申基生物科技有限公司 一种微小核糖核酸miR-34a偶联探针及其制备方法
WO2025050037A1 (en) * 2023-08-31 2025-03-06 The Regents Of The University Of Colorado, A Body Corporate Microrna-15b antagomir and cerium oxide nanoparticles, and uses of same for treatment of intrauterine growth restriction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DK2205737T3 (da) * 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
DE102007052114B4 (de) * 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
GB0814302D0 (en) * 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
KR20120047214A (ko) * 2009-05-20 2012-05-11 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심근경색 후 리모델링 및 심부전에 관련된 마이크로―ｒｎａ의 확인

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BONAUER A. et al., MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice, Science, 2009, V. 324, N. 5935, p. 1710-1713. *
BONAUER A. et al., MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice, Science, 2009, V. 324, N. 5935, p. 1710-1713. NAFEE N. at al., Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides, Nanomedicine: Nanotechnology, Biology, and Medicine, 2007, V. 3, N. 3, p. 173-183. LUO G. et al., RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles, Cancer biology and therapy, 2009, V. 8, N. 7, p. 594-598. D’ANGELO I. et al., Improved delivery of angiogenesis inhibitors from PLGA: poloxamer blend micro-and nanoparticles, Journal of microencapsulation, 2010, V. 27, N. 1, p. 57-66. CHENG C. et al., Polymer Nanoparticle-Mediated Delevery of MicroRNA Inhibition and Alternative Splicing, Molecular pharmaceutics, 2012, V. 9, N. 5, p. 1481-1488. JAIN R.A., The manufacturing techniques of various drug loaded biodeg *
CHENG C. et al., Polymer Nanoparticle-Mediated Delevery of MicroRNA Inhibition and Alternative Splicing, Molecular pharmaceutics, 2012, V. 9, N. 5, p. 1481-1488. *
D’ANGELO I. et al., Improved delivery of angiogenesis inhibitors from PLGA: poloxamer blend micro-and nanoparticles, Journal of microencapsulation, 2010, V. 27, N. 1, p. 57-66. *
JAIN R.A., The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide)(PLGA) devices, Biomaterials, 2000, V. 21, N. 23, p.2475-2490. *
LUO G. et al., RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles, Cancer biology and therapy, 2009, V. 8, N. 7, p. 594-598. *
NAFEE N. at al., Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides, Nanomedicine: Nanotechnology, Biology, and Medicine, 2007, V. 3, N. 3, p. 173-183. *
КОРОБОВ Г. А. и др., Ишемическая болезнь сердца: регулирование с помощью микроРНК, Кардиологический вестник, 2011, Т. 6, N. 2, с. 5-9. *

Also Published As

Publication number Publication date
KR20160018451A (ko) 2016-02-17
US20150352055A1 (en) 2015-12-10
PL2759595T3 (pl) 2017-09-29
EP2759595A1 (en) 2014-07-30
CA2898958A1 (en) 2014-07-31
JP2016506923A (ja) 2016-03-07
ES2606636T3 (es) 2017-03-24
WO2014115103A1 (en) 2014-07-31
HUE032125T2 (en) 2017-08-28
AU2014208419A1 (en) 2015-08-13
EP2948551A1 (en) 2015-12-02
CN105229151A (zh) 2016-01-06
RU2015134770A (ru) 2017-03-03
BR112015017650A2 (pt) 2017-11-21
ZA201505602B (en) 2017-05-31
ES2688160T3 (es) 2018-10-31
EP2759595B1 (en) 2016-09-14
HK1219753A1 (zh) 2017-04-13
EP2948551B1 (en) 2018-05-02
MX2015009323A (es) 2016-04-04

Similar Documents

Publication Publication Date Title
EP2948551B1 (en) Composition comprising an encapsulated antagomir
AU2018214137B2 (en) MiRNA and its diagnostic therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
US9457046B2 (en) Compounds for the treatment of ischemic injury
US20210087567A1 (en) Therapeutic oligonucleotides
JP2011256204A5 (enExample)
JP2015525081A5 (enExample)
EP2700414B1 (en) Self-gelatinizable nucleic acid
EP3329004B1 (en) Therapeutic oligonucleotides
Wang et al. MicroRNA delivery based on nanoparticles of cardiovascular diseases
EP4634386A1 (en) Antisense oligonucleotide analogs of mir-29 and uses thereof
JPWO2015133637A1 (ja) マイクロｒｎａ封入ナノ粒子及びその医薬用途
CN102140469B (zh) 人miR-1233反义核酸及其应用
KR20190134753A (ko) 골 손실 및 근육 기능 감소와 관련된 병리학적 상태를 치료하는데 이용하기 위한 마이크로rna 19a/19b
US20250161398A1 (en) Design and development of a novel messenger rna therapeutic to treat atherosclerosis
CN120584186A (zh) 用于在静脉血栓栓塞的治疗中使用的药物组合物
WO2022251322A1 (en) Methods of using mir-3075-5p to improve insulin sensitivity and compositions therefor
BR122024021791A2 (pt) Oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica
BR112018001782B1 (pt) Oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200124